

Application No. 10/550,038
Amendment Dated 05/18/2006
Reply to Office Action of 04/13/2006


11 of 11

Remarks/Arguments

Claims 12 and 13 are as originally presented. Claims 2, 4, and 8 were previously amended. Claims 1, 6, and 11 are currently amended. Claims 3, 5, 7, 9, and 10 are cancelled. The amended claims are supported by the specification and do not present any new matter.

Applicants are required to make an election in light of the Examiner's Action mailed April 13, 2006. Applicants discussed the restriction requirement with the Examiner on May 15, 2006 and proposed an alternative group for election. In light of that discussion, Applicants amended claim 1 and subsequent claims as provided herein. Applicants communicated the proposed changes with the Examiner by facsimile transmittal. The Examiner indicated that he was amenable to the Applicants' proposed alternative group for election.

Applicants further identify the compound of Example 8 (see page 56 of the Specification) as a species within the scope of amended claim 1. The chemical structure of Example 8 is provided here for the Examiner's convenience.

**Example 8**

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100869-1P US.

Respectfully submitted,

Name: Heidi Berven
Dated: 05/18/2006
Reg. No.: 48,951
Phone No.: 781-839-4336
Global Intellectual Property, Patents,
AstraZeneca R&D Boston,
35, Gatehouse Drive,
Waltham,
MA 02451